Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTFA guidelines

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic, Toiletry and Fragrance Association is requesting public comments on two new and one revised Safety Evaluation Guidelines by July 8, CTFA announces. The two new guidelines for genotoxicity and reproductive and developmental toxicity testing describe both in vivo and in vitro models, while the revised guidelines on photoirritation/photoallergy include in vivo, in vitro and clinical test methods, association notes. CTFA Safety Evaluation Guidelines "provide manufacturers with guidance regarding the use of preclinical and clinical safety testing as means to substantiate the safety of both ingredients and finished cosmetic products"...

You may also be interested in...



CTFA guidelines

The Cosmetic, Toiletry and Fragrance Association is requesting comments on a new Safety Evaluation Guideline on in vitro test methods for evaluating skin absorption; comments are due by Sept. 25. The association's guidelines "provide manufacturers with guidance regarding the use of preclinical and clinical safety testing as a means to substantiate the safety of both ingredients and finished cosmetic products." In June, CTFA requested comments on two new guidelines for genotoxicity and reproductive and developmental toxicity testing as well as revised guidelines on photoirritation/photoallergy (1"The Rose Sheet" June 26, 2006, In Brief)...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 
UsernamePublicRestriction

Register

RS014028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel